As the incidence of COVID-19 increases with time, more and more efforts are made to pave
a way out for the therapeutic strategies to deal with the disease progression. Inflammation …

Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects
of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial …

Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the
JAK/STAT signaling pathway, one of the critical cellular signaling pathways involved in the …

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused the unprecedented COVID-19 pandemic, which has infected over 178 million people …

Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19 |
Science Immunology news careers commentary Journals Science Science brought to you …

After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
outbreak of coronavirus disease 2019 (COVID-19) commenced across the world …

In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly …

Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …

ABSTRACT SARS-CoV-2 can infect multiple organs, including lung, intestine, kidney, heart,
liver, and brain. The molecular details of how the virus navigates through diverse cellular …